GDTC
Income statement / Annual
Last year (2024), CytoMed Therapeutics Limited's total revenue was $52.01 K,
a decrease of 82.10% from the previous year.
In 2024, CytoMed Therapeutics Limited's net income was -$1.88 M.
See CytoMed Therapeutics Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$52.01 K |
$290.56 K |
$0.00 |
$84.18 K |
$44.92 K |
$0.00 |
| Cost of Revenue |
$22.73 K
|
$2.82 K
|
$81.03 K
|
$2.59 K
|
$3.50 K
|
$0.00
|
| Gross Profit |
$52.38 K
|
$381.92 K
|
-$81.03 K
|
$81.59 K
|
$41.43 K
|
$0.00
|
| Gross Profit Ratio |
1.01
|
1.31
|
0
|
0.97
|
0.92
|
0
|
| Research and Development Expenses |
$1.43 M
|
$1.20 M
|
$1.13 M
|
$806.45 K
|
$784.20 K
|
$323.98 K
|
| General & Administrative Expenses |
$1.24 M
|
$344.25 K
|
$443.29 K
|
$433.47 K
|
$112.32 K
|
$0.00
|
| Selling & Marketing Expenses |
$23.78 K
|
$25.24 K
|
$0.00
|
$1.83 K
|
$4.67 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.27 M
|
$370.67 K
|
$443.29 K
|
$435.31 K
|
$116.99 K
|
$29.72 K
|
| Other Expenses |
-$823.10 K
|
$0.00
|
$41.26 K
|
-$304.61 K
|
-$9.52 K
|
$126.51 K
|
| Operating Expenses |
$1.87 M
|
$1.58 M
|
$1.62 M
|
$937.15 K
|
$891.67 K
|
$480.22 K
|
| Cost And Expenses |
$2.68 M
|
$1.58 M
|
$1.70 M
|
$939.75 K
|
$895.17 K
|
$480.22 K
|
| Interest Income |
$237.70 K
|
$212.72 K
|
$1.52 K
|
$2.51 K
|
$79.71 K
|
$20.06 K
|
| Interest Expense |
$15.20 K
|
$38.18 K
|
$90.77 K
|
$87.58 K
|
$79.71 K
|
$0.00
|
| Depreciation & Amortization |
$91.59 K
|
$77.47 K
|
$293.32 K
|
$243.92 K
|
$220.99 K
|
$97.23 K
|
| EBITDA |
-$1.79 M |
-$2.94 M |
-$1.10 M |
-$1.05 M |
-$776.21 K |
-$349.62 K |
| EBITDA Ratio |
-34.43
|
-10.11
|
0
|
-12.45
|
-17.28
|
0
|
| Operating Income Ratio |
-50.5
|
-11.01
|
0
|
-16.61
|
-22.33
|
0
|
| Total Other Income/Expenses Net |
$739.13 K
|
$122.21 K
|
-$572.86 K
|
-$128.35 K
|
-$400.12 K
|
-$152.39 K
|
| Income Before Tax |
-$1.89 M
|
-$3.08 M
|
-$2.27 M
|
-$1.53 M
|
-$1.40 M
|
-$632.61 K
|
| Income Before Tax Ratio |
-36.29
|
-10.59
|
0
|
-18.22
|
-31.24
|
0
|
| Income Tax Expense |
$0.00
|
$486.17
|
$1.19 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$1.88 M
|
-$3.13 M
|
-$2.27 M
|
-$1.53 M
|
-$1.47 M
|
-$632.61 K
|
| Net Income Ratio |
-36.21
|
-10.78
|
0
|
-18.22
|
-32.66
|
0
|
| EPS |
-0.16 |
-0.29 |
-0.3 |
-0.22 |
-0.25 |
-0.081 |
| EPS Diluted |
-0.16 |
-0.29 |
-0.3 |
-0.22 |
-0.25 |
-0.11 |
| Weighted Average Shares Out |
$11.54 M
|
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Weighted Average Shares Out Diluted |
$11.54 M
|
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Link |
|
|
|
|
|
|
